A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 - January 2019.

@article{Marcantoni2020ASR,
  title={A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 - January 2019.},
  author={Walter S. Marcantoni and Bertine Sandra Akoumba and Maggy Wassef and Julie Mayrand and Hin-lun Henry Lai and St{\'e}phane Richard-Devantoy and Sylvie Beauchamp},
  journal={Journal of affective disorders},
  year={2020},
  volume={277},
  pages={
          831-841
        }
}

Strategies to Prolong Ketamine’s Efficacy in Adults with Treatment-Resistant Depression

Different treatment modalites including pharmacological interventions, manualized-based psychotherapies, electroconvulsive therapy, transcranial magnetic stimulation, and intravenous monotherapy were examined to determine their impact on the prolongation of antidepressant effects following acute ketamine treatment.

Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses.

Ketamine and esketamine showed a significant antidepressant action within a few hours or days after administration; however, the long-term efficacy and safety are lacking.

Ketamine as an adjunctive therapy for major depression - a randomised controlled pragmatic pilot trial (Karma-Dep Trial)

This first pragmatic pilot trial of adjunctive serial ketamine infusions for hospitalised depression suggests that a definitive trial ofadjunctive ketamine is feasible and generally safe and well tolerated.

Ketamine as an adjunctive therapy for major depression - a randomised controlled pragmatic pilot trial (Karma-Dep Trial).

This first pragmatic pilot trial of adjunctive serial ketamine infusions for hospitalised depression suggests that a definitive trial ofadjunctive ketamine is feasible and generally safe and well tolerated.

Protocol for the Ketamine for Postoperative Avoidance of Depressive Symptoms (K-PASS) feasibility study: A randomized clinical trial

This pilot study will evaluate the feasibility of a future large comparative effectiveness trial of ketamine to reduce depressive symptoms in postsurgical patients.

Role of the Pharmacist in Managing Treatment-Resistant Depression: A Focus on Ketamine

Extending the reach of these novel psychiatric treatments in both tertiary and primary care settings creates an emerging role for pharmacists in the collaborative effort to better manage treatment-resistant depression.

Active mechanisms of ketamine-assisted psychotherapy: A systematic review.

Vital Sign Changes During Intravenous Ketamine Infusions for Depression

Physiologic sensitivity to the effects of ketamine may predict treatment responsiveness, and blood pressure and heart rate did not always increase, and possible influences on physiologic responses were examined.

References

SHOWING 1-10 OF 62 REFERENCES

A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes

It is suggested that single administrations ketamine are efficacious in the rapid treatment of unipolar and bipolar depression and the potential efficacy of other glutamatergic agents.

Ketamine and depression: a narrative review

The level of proof of efficacy remains low and more RCTs are needed to explore efficacy and safety issues of ketamine in depression, as there is a lack of data concerning ketamine with repeated administration at higher doses.

Ketamine administration in depressive disorders: a systematic review and meta-analysis

The present meta-analysis confirms ketamine’s efficacy in depressive disorders in non-ECT studies, as well as in ECT studies, and further studies are warranted to detail efficacy in bipolar disorders and other specific depressed populations.

Rapid Antidepressant Response with Ketamine: Is it the Solution to Resistant Depression?

The ketamine infusion was effective in reducing the HDRS scores, and the change remained significant from minute 80 to day 3 postinfusion at each time point, but the change was not significant at any time after day 3.

Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.

Ketamine demonstrated rapid antidepressant effects in an optimized study design, further supporting NMDA receptor modulation as a novel mechanism for accelerated improvement in severe and chronic forms of depression.

Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD)

The results suggest that there is a range of effective, subanesthetic doses of IV ketamine in TRD, including standard dose and high dose of intravenous ketamine were superior to active placebo, and post hoc pairwise comparisons controlling for multiple comparisons suggested this.

Maintenance Ketamine Therapy for Treatment-Resistant Depression

Maintenance ketamine treatments may be an effective way of maintaining treatment response in some ketamine responders and future research is required to determine optimal length of treatment in those who respond to ketamine and to track adverse effects over a longer time.

A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.

OBJECTIVE Ketamine, an N-methyl-d-aspartate glutamate receptor antagonist, has demonstrated a rapid-onset antidepressant effect in patients with treatment-resistant depression. This study evaluated
...